The ADVANCE (ADjuVANt Chemotherapy in the Elderly) trial assessed the feasibility of two (neo)adjuvant chemotherapy regimens in parallel-enrolling cohorts of older persons (≥70 years) with human epidermal growth factor receptor 2 (HER2)-negative BC [16]. This evidence concerns the gene ERBB2 and breast cancer.